Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd.
Summary
Flumatinib is an orally available TKI with high selectivity and potency against BCR-ABL1 kinase. It's a multi-center, open-label, real world study to explore the efficacy and safety of Flumatinib versus Imatinib as the first line therapy in patients with chronic myleiod leukemia(CML) in chronic phase(CP).
Official title: Evaluating the Efficacy and Safety of Flumatinib Versus Imatinib for in Patients With Newly Diagnosed Chronic Myeloid Leukemia (CML)-in Chronic Phase (CP): A Multicenter, Open-label, Real World Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
2400
Start Date
2022-04-30
Completion Date
2028-04-30
Last Updated
2022-05-10
Healthy Volunteers
No
Conditions
Interventions
Flumatinib
Flumatinib 600mg orally daily
Imatinib
Imatinib 400mg orally daily (Reference drug instructions)
Locations (1)
Institute of Hematology and Oncology, Harbin The First Hospital
Harbin, Heilongjiang, China